Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol + remifentanil vs ketofel for electroconvulsive therapy in psychotic patients
IRCT20141209020258N129Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of propofol and remifentanil in Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Seizure duration and Hemodynamic parameters. Started May 2019; status: completed.
02
Drugs
propofolremifentanil
03
Conditions
Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on IRCT20141209020258N129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N129.